We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

October 2, 2014

JAZZ PHARMACEUTICALS, INC. et al v. PAR PHARMACEUTICAL, INC.

Track this case

Case Number:

2:14-cv-06150

Court:

New Jersey

Nature of Suit:

Patent

Judge:

Esther Salas

Firms

Companies

Sectors & Industries:

View recent docket activity


Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.


Coverage

  1. January 14, 2015

    CORRECTED: PTAB Nixes Biz Method Review Of Jazz Drug Patents

    The Patent Trial and Appeal Board on Tuesday rejected petitions challenging Jazz Pharmaceuticals Inc.'s patents for the narcolepsy drug Xyrem under the America Invents Act business method review program, ruling that the patents are not financial in nature, as required by the program. (Correction: An earlier story incorrectly stated that this decision was the first time the PTAB has ruled that a patent being challenged under the business review program was not related to financial services. The error has been corrected.)


Parties

To view the parties, register now.